GO
Loading...

Pharmaceuticals

More

  • Crestor Competition Overshadows AstraZeneca Results Thursday, 1 Nov 2007 | 8:11 AM ET

    AstraZeneca profits fell 14 percent in the third quarter, hit by competition from cheap generics plus acquisition and restructuring charges, the Anglo-Swedish drugmaker said on Thursday.

  • On the Line: Nastech Pharma CEO Dr. Stephen Quay Wednesday, 31 Oct 2007 | 8:02 PM ET

    The chief executive talks up his approach to business, a pesky payment owed by Procter & Gamble and why the company will succeed where rivals have failed.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Eli Lilly: Will They Get Lucky With 'One A Day' Cialis? Wednesday, 31 Oct 2007 | 3:36 PM ET
    Eli Lilly

    Today's the day Eli Lilly was expected to get a Food and Drug Administration decision on the first-ever one-a-day impotence drug. Right now, the company sells Cialis for use as needed. But men could pop this one every day--like an aspirin or multi-vitamin--so the drug would always be "on boa

  • Amylin's Once A Week Byetta: Good Is Not Enough Wednesday, 31 Oct 2007 | 12:21 PM ET
    Byetta Needle

    This morning Amylin Pharmaceuticals, Eli Lilly and Alkermes announced the highly anticipated test results on their once-a-week, Type 2 diabetes drug. One analyst recently called this the most important biotech data of the second half of this year. Many expect the drug to become a multi-billion dollar blockbuster.

  • McKesson Shares Surge on Strong Earnings Wednesday, 31 Oct 2007 | 11:38 AM ET

    Shares of McKesson jumped to their highest price since 1999 on Wednesday, the day after the drug wholesaler posted better-than-expected quarterly results and raised its outlook for the full year.

  • Sanofi Raises Outlook on Strong Third-Quarter Profit Wednesday, 31 Oct 2007 | 5:39 AM ET

    French drugmaker Sanofi-Aventis raised its full-year 2007 outlook on Wednesday as it reported a forecast-beating 9.1 percent rise in third-quarter profit, helped notably by vaccines and cost cuts.

  • McKesson Profit Rises 8%; Company Boosts Outlook Tuesday, 30 Oct 2007 | 5:16 PM ET
    McKesson

    Pharmaceutical wholesaler McKesson  reported that its quarterly profit rose a better-than-expected 8 percent, led by increased demand for its drug distribution business, and the company raised its full-year earnings forecast.

  • Genentech "Sees The Light" On Avastin? Tuesday, 30 Oct 2007 | 1:05 PM ET

    In a remarkably candid "Open Letter" on the homepage of its web site Genentech is taking a step back from implementing its new restrictive policy over the use of the cancer drug Avastin in lieu of Lucentis for age-related macular degeneration (AMD), the leading cause of adult blindness. I had recently blogged about the company's action and angry reader response to it.

  • ASCO: 'Open Door Policy' Levels Playing Field Monday, 29 Oct 2007 | 3:37 PM ET

    TheStreet.com's senior biotech writer Adam Feuerstein broke this story earlier today, but now we've confirmed it independently. The American Society of Clinical Oncology (ASCO) is changing its ways.

  • Lipitor

    Pfizer has been using Dr. Robert Jarvik, the inventor of the Jarvik Artificial Heart, for quite some time now as its Lipitor "celebrity" pitchman. But recently I've noticed something remarkable creeping into his copy--the script he reads for TV and radio spots and the text that appears in the print ads.

  • Merck, Sanofi, Glaxo Get "Shot In The Arm" From U.K. Friday, 26 Oct 2007 | 12:52 PM ET

    British health authorities today announced that starting next fall, all 12- and 13-year-old girls will have to get the controversial shots to prevent the sexually transmitted virus that can lead to cervical cancer. Merck and Sanofi-Aventis are partners on the vaccine Gardasil and the UK-based GlaxoSmithKline makes a similar one Cervarix.

  • Eli Lilly: "Bloom" Is Off The Pipeline Thursday, 25 Oct 2007 | 11:43 AM ET
    Eli Lilly

    If the stock closes down at least 4.46% today (as I write this it is off nearly 7%) Eli Lilly will suffer its worst one-day loss in more than four years, according to our resident statistical expert Robert Hum. If it were to close off more than 7.79%, Hum says it would be the stock's biggest one-day fall since Oct. 23, 2002--almost five years to the day.

  • Health Care Stocks to Watch Thursday, 25 Oct 2007 | 10:55 AM ET

    Even as much of the economy contracts, health care continues to grow, and investment opportunities continue to grow with it. What to choose among those investment opportunities? Analyst Michael Magiera of Manning & Napier looks past some of the more volatile pharmaceutical stocks.

  • Bristol-Myers Profit Jumps on Higher Drug Revenue Thursday, 25 Oct 2007 | 9:00 AM ET

    Bristol-Myers Squibb Thursday said third-quarter earnings more than doubled on higher drug revenue, including a strong rebound for its Plavix blood-clot preventer, and raised its 2007 profit forecast.

  • Eli Lilly Halts Two Drug Studies; Shares Fall Wednesday, 24 Oct 2007 | 6:50 PM ET

    Eli Lilly said it stopped giving its experimental blood-clot preventer prasugrel to heart patients in two small trials, noting that the dosage of the drug may have to be adjusted for certain types of patients.

  • Amgen: Is There A Takeout Scenario? Wednesday, 24 Oct 2007 | 1:15 PM ET

    On a day when the markets are selling off, shares of the world's biggest biotech company--by sales--are holding their own. There are a few things that could be buoying Amgen's stock. The company won a huge patent battle yesterday, it reports earnings after the closing bell today and an analyst has upgraded the stock to "Outperform".

  • European Stocks Close Lower after US Housing Slowdown Wednesday, 24 Oct 2007 | 12:18 PM ET

    Major European indexes closed lower after U.S. existing-homes sales fell 8% in September to a record low 5.04 million unit because of troubles in the subprime mortgages and credit markets.

  • Glaxo's Avandia Nose Dive: What It Means Wednesday, 24 Oct 2007 | 11:48 AM ET

    Shares in the world's second biggest drug company, GlaxoSmithKline, are giving back all of yesterday's gains in early trading this morning. That's because sales of its embattled diabetes drug, Avandia and other Avandia-related products took a huge dive in the third quarter. Down 48% in the U.S. from the same time last year.

  • Glaxo Profit Hit by Avandia Sales Slump Wednesday, 24 Oct 2007 | 11:46 AM ET
    The company logo of GlaxoSmithKline, is seen on the headquarters building in London, Wednesday May 10, 2006. GlaxoSmithKline PLC said Wednesday it has been granted a High Court injunction against animal rights activists who sent threats to the drugmaker's shareholders, barring them from sending more letters or revealing private information about the investors. (AP Photo/Alastair Grant)

    GlaxoSmithKline posted a lower profit on Wednesday due to tumbling sales of its Avandia diabetes drug, generic competition and pressure on top-selling asthma treatment Advair, and said it would cut jobs to save costs.

  • Cancer Drug Erbitux Helps German Merck's Results Wednesday, 24 Oct 2007 | 5:42 AM ET

    German pharmaceutical and chemical company Merck KGaA said Wednesday that its third-quarter profit fell 75 percent because of costs related to its purchase of Swiss biotech firm Serono.